Background
==========

We have implicated the human chaperone protein BiP in the pathogenesis of rheumatoid arthritis (RA). Increased immunoglobulin binding of RA sera to BiP is seen on Western blot analysis.

Methods
=======

We now describe an ELISA developed to enable rapid screening of sera for antibody reactivity to BiP.

Results
=======

Specificity of the assay has been shown by free ligand competition and extensive correlations with other immunological parameters. We show no correlation between anti-BiP and rheumatoid factor or with cyclic citrullinated peptide. We confirm the increased binding of immunoglobulin to BiP in the sera of a group of patients with RA (*n* = 96) in comparison with controls (*n* = 96). Our data show a specificity of 71% and a sensitivity of 73% for RA. Furthermore, these data show that antibody will bind to a nonglycosylated form of BiP, since the protein is produced in an *Escherichia coli* expression system.

Conclusion
==========

We have developed a robust protocol for the detection of antibodies to the human chaperone molecule BiP. Our data show an elevated antibody response to BiP in RA patients and hence support a role for this molecule in the disease.
